PROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its peers? We will compare PROCEPT BioRobotics to related businesses based on the strength of its dividends, risk, valuation, analyst recommendations, earnings, profitability and institutional ownership.
Earnings and Valuation
This table compares PROCEPT BioRobotics and its peers revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| PROCEPT BioRobotics | $337.34 million | -$95.57 million | -9.90 |
| PROCEPT BioRobotics Competitors | $1.89 billion | $137.23 million | 10.69 |
PROCEPT BioRobotics’ peers have higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
89.5% of PROCEPT BioRobotics shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 4.0% of PROCEPT BioRobotics shares are owned by insiders. Comparatively, 14.8% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Risk & Volatility
PROCEPT BioRobotics has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, PROCEPT BioRobotics’ peers have a beta of 2.50, suggesting that their average share price is 150% more volatile than the S&P 500.
Profitability
This table compares PROCEPT BioRobotics and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PROCEPT BioRobotics | -32.53% | -30.62% | -22.10% |
| PROCEPT BioRobotics Competitors | -278.23% | -150.07% | -21.87% |
Analyst Recommendations
This is a breakdown of current recommendations for PROCEPT BioRobotics and its peers, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PROCEPT BioRobotics | 2 | 9 | 2 | 3 | 2.38 |
| PROCEPT BioRobotics Competitors | 4251 | 10479 | 18202 | 824 | 2.46 |
PROCEPT BioRobotics presently has a consensus price target of $25.50, suggesting a potential upside of 32.81%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 25.59%. Given PROCEPT BioRobotics’ higher possible upside, equities research analysts plainly believe PROCEPT BioRobotics is more favorable than its peers.
Summary
PROCEPT BioRobotics peers beat PROCEPT BioRobotics on 8 of the 13 factors compared.
About PROCEPT BioRobotics
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.
